Render Target: STATIC
Render Timestamp: 2024-12-27T11:38:16.070Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-09-30 01:59:51.918
Product last modified at: 2024-12-06T14:30:08.979Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

OSMR (F9Q2W) Rabbit mAb #95443

Filter:
  • WB

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 180, 160
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    OSMR (F9Q2W) Rabbit mAb recognizes endogenous levels of total OSMR protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the carboxy terminus of human OSMR protein.

    Background

    OSMR, also known as oncostatin-M-specific receptor subunit beta or interleukin-31 receptor subunit beta, is a member of the type I cytokine receptor family (1,2). This protein heterodimerizes with interleukin signal transducers, such as gp130, to form the binding receptor of oncostatin M (OSM) protein (3). Binding of the OSM ligand to OSMR complexes triggers activation of Jak1 and Jak2, which phosphorylate tyrosine residues in the cytoplasmic domains of both gp130 and OSMR. Downstream signaling along the Jak1 pathway leads to activation of the MAPK cascade, PI3K cascade, and STAT3 (4,5). OSMR activation of the STAT3/SMAD3 axis regulates expression of genes responsible for inducing a mesenchymal/cancer stem cell phenotype (6). Research studies have shown that OSMR is overexpressed in several cancer types and may be associated with adverse clinical outcomes (7,8). Because its expression is more restricted to stromal and other nonhaematopoietic cells, targeting OSMR may provide a novel means of inhibiting inflammatory pathology while preserving protective immunity (5).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.